Merus gains on positive data from cancer therapy trial

Merus NV

17/04/2023 16:40

** Shares of cancer drug developer Merus NV  MRUS.O  rise
13.8% to $24.8
    ** Co says interim early- to mid-stage trial data for its
bispecific antibody petosemtamab showed clinically meaningful
activity
    ** The antibody was tested in previously treated head and
neck squamous cell carcinoma (HNSCC) patients
    ** Overall response rate (ORR) of 37% observed in 43
eligible patients and 6 months median duration of response seen,
as of Feb 1 data cutoff date - MRUS 
    ** Petosemtamab continued to demonstrate a manageable safety
profile - co
    ** Co adds that end-of-phase meeting with U.S. FDA has
provided clarity to potential registration path in HNSCC 
    ** YTD, stock up 60.1%, including session's gain 


    

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))